BGMS · Bio Green Med Solution, Inc.

Bio Green Med Solution, Inc. (BGMS) reported a strategic pivot in 2025, shifting from biopharmaceuticals to fire safety via the September 12 acquisition of Fitters Sdn. Bhd., which delivered $747K in full-year product revenue and $666K in Q4, with cost of sales at $609K and $545K respectively. This marked the company's first revenue from its new core business. R&D expenses plummeted to $848K for the year from $6,655K in 2024, reflecting the January 24, 2025 liquidation of UK subsidiary Cyclacel Limited (yielding a $4.9M deconsolidation gain) and the October sale of plogosertib assets for $300K plus up to $170K milestone. General and administrative expenses rose to $7.7M from $5.4M due to two changes of control. Overall, operating loss narrowed to $8.4M from $12.0M, with other income of $5.4M driving net loss to $3.0M from $11.2M. Balance sheet strengthened with cash at $3.5M (up from $3.1M), total assets $8.2M, positive equity $6.8M, and operating cash burn halved to $4.8M. CEO Datuk Dr. Doris Wong highlighted strengthened balance sheet and growth focus. Cash funds operations into Q3 2026. A $0.15/share preferred dividend was paid in February 2026, signaling confidence amid the transition.